Johannes-Peter Stasch

List of Publications by Year
in descending order

145	9,133	31976	42399
papers	citations	53 h-index	92 g-index

151	151	151	6080
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Discovery of the Soluble Guanylate Cyclase Activator Runcaciguat (BAY 1101042). Journal of Medicinal Chemistry, 2021, 64, 5323-5344.	6.4	38
2	Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease. Naunyn-Schmiedeberg's Archives of Pharmacology, 2021, 394, 2363-2379.	3.0	13
3	Soluble guanylate cyclase stimulators and their potential use: a patent review. Expert Opinion on Therapeutic Patents, 2021, 31, 203-222.	5.0	22
4	Soluble GC stimulators and activators: Past, present and future. British Journal of Pharmacology, 2021, , .	5.4	45
5	Singlet molecular oxygen regulates vascular tone and blood pressure in inflammation. Nature, 2019, 566, 548-552.	27.8	84
6	Nitric Oxideâ€“Independent Soluble Guanylate Cyclase Activation Improves Vascular Function and Cardiac Remodeling in Sickle Cell Disease. American Journal of Respiratory Cell and Molecular Biology, 2018, 58, 636-647.	2.9	25
7	Identification of a soluble guanylate cyclase in RBCs: preserved activity in patients with coronary artery disease. Redox Biology, 2018, 14, 328-337.	9.0	59
8	Soluble Guanylate Cyclase Stimulators and Activators. Handbook of Experimental Pharmacology, 2018, 264, 355-394.	1.8	104
9	Response to: Comment on â€œEffect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Bandingâ€• BioMed Research International, 2018, 2018, 1-2.	1.9	0
10	Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding. BioMed Research International, 2018, 2018, 1-9.	1.9	29
11	Urinary cGMP predicts major adverse renal events in patients with mild renal impairment and/or diabetes mellitus before exposure to contrast medium. PLoS ONE, 2018, 13, e0195828.	2.5	6
12	Nitric oxideâ€“sensitive guanylyl cyclase stimulation improves experimental heart failure with preserved ejection fraction. JCI Insight, 2018, 3, .	5.0	27
13	Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension. Chest, 2017, 151, 468-480.	0.8	79
14	Inhibition of the <scp>TGF</scp>Î² signalling pathway by <scp>cGMP</scp> and <scp>cGMP</scp>â€dependent kinase I in renal fibrosis. FEBS Open Bio, 2017, 7, 550-561.	2.3	27
15	Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure. Journal of Medicinal Chemistry, 2017, 60, 5146-5161.	6.4	133
16	Chronic intratracheal application of the soluble guanylyl cyclase stimulator BAY 41-8543 ameliorates experimental pulmonary hypertension. Oncotarget, 2017, 8, 29613-29624.	1.8	9
17	Soluble guanylate cyclase as an alternative target for bronchodilator therapy in asthma. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E2355-62.	7.1	57
18	Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice. International Journal of Cardiology, 2016, 216, 85-91.	1.7	28

#	Article	IF	Citations
19	Riociguat and cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats. BMC Pharmacology & Toxicology, 2015, 16, .	2.4	0
20	Stimulation of soluble guanylyl cyclase protects against obesity by recruiting brown adipose tissue. Nature Communications, 2015, 6, 7235.	12.8	85
21	The soluble guanylate cyclase stimulator riociguat and the soluble guanylate cyclase activator cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats. European Journal of Pharmacology, 2015, 767, 1-9.	3.5	14
22	Renal effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence. Current Opinion in Pharmacology, 2015, 21, 95-104.	3.5	93
23	Cardiovascular and pharmacological implications of haem-deficient NO-unresponsive soluble guanylate cyclase knock-in mice. Nature Communications, 2015, 6, 8482.	12.8	64
24	Translational In Vivo Models for Cardiovascular Diseases. Handbook of Experimental Pharmacology, 2015, 232, 223-234.	1.8	6
25	Chronic Activation of Heme Free Guanylate Cyclase Leads to Renal Protection in Dahl Salt-Sensitive Rats. PLoS ONE, 2015, 10, e0145048.	2.5	24
26	Î±1-A680T Variant in GUCY1A3 as a Candidate Conferring Protection From Pulmonary Hypertension Among Kyrgyz Highlanders. Circulation: Cardiovascular Genetics, 2014, 7, 920-929.	5.1	23
27	Role of soluble guanylate cyclase in renal hemodynamics and autoregulation in the rat. American Journal of Physiology - Renal Physiology, 2014, 307, F1003-F1012.	2.7	12
28	Stimulation of Soluble Guanylate Cyclase Prevents Cigarette Smokeâ€“induced Pulmonary Hypertension and Emphysema. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 1359-1373.	5.6	80
29	Influence of cinaciguat on gastrointestinal motility in apoâ€‹scp›sGC‹/scp› mice. Neurogastroenterology and Motility, 2014, 26, 1573-1585.	3.0	3
30	Nitric Oxide and Heat Shock Protein 90 Activate Soluble Guanylate Cyclase by Driving Rapid Change in Its Subunit Interactions and Heme Content. Journal of Biological Chemistry, 2014, 289, 15259-15271.	3.4	62
31	Nucleotidyl cyclase activity of soluble guanylyl cyclase in intact cells. Biochemical and Biophysical Research Communications, 2014, 443, 1195-1199.	2.1	39
32	NO-independent stimulation or activation of soluble guanylyl cyclase during early reperfusion limits infarct size. Cardiovascular Research, 2014, 101, 220-228.	3.8	34
33	Structure/Activity Relationships of (M)ANT- and TNP-Nucleotides for Inhibition of Rat Soluble Guanylyl Cyclase ‹i›Î±‹/i›‹sub›1‹/sub›‹i›Î²‹/i›‹sub›1‹/sub›. Molecular Pharmacology, 2014, 85, 598-607.	2.3	8
34	The Chemistry and Biology of Soluble Guanylate Cyclase Stimulators and Activators. Angewandte Chemie - International Edition, 2013, 52, 9442-9462.	13.8	173
35	Chronic activation of heme free soluble guanylate cyclase leads to cardio-renal protection in experimental hypertension. BMC Pharmacology & Toxicology, 2013, 14, .	2.4	0
36	Insights into BAY 60-2770 Activation and ‹i›S‹/i›-Nitrosylation-Dependent Desensitization of Soluble Guanylyl Cyclase via Crystal Structures of Homologous Nostoc H-NOX Domain Complexes. Biochemistry, 2013, 52, 3601-3608.	2.5	52

#	Article	IF	Citations
37	Analysis of Erectile Responses to BAY 41-8543 and Muscarinic Receptor Stimulation in the Rat. Journal of Sexual Medicine, 2013, 10, 704-718.	0.6	16
38	Identification of acidic heterocycle-substituted 1H-pyrazolo[3,4-b]pyridines as soluble guanylate cyclase stimulators. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 1197-1200.	2.2	9
39	The Selective Rho-kinase Inhibitor Azaindole-1 Has Long-lasting Erectile Activity in the Rat. Urology, 2013, 81, 465.e7-465.e14.	1.0	14
40	Receptor Binding Assay for NO-Independent Activators of Soluble Guanylate Cyclase. Methods in Molecular Biology, 2013, 1020, 205-214.	0.9	2
41	Direct sGC Activation Bypasses NO Scavenging Reactions of Intravascular Free Oxy-Hemoglobin and Limits Vasoconstriction. Antioxidants and Redox Signaling, 2013, 19, 2232-2243.	5.4	26
42	Soluble guanylate cyclase: a potential therapeutic target for heart failure. Heart Failure Reviews, 2013, 18, 123-134.	3.9	118
43	The cGMP Signaling Pathway as a Therapeutic Target in Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association, 2013, 2, e000536.	3.7	131
44	Effects of Different Pulmonary Vasodilators on Arterial Saturation in a Model of Pulmonary Hypertension. PLoS ONE, 2013, 8, e73502.	2.5	15
45	Soluble Guanylate Cyclase Stimulators in Pulmonary Hypertension. Handbook of Experimental Pharmacology, 2013, 218, 279-313.	1.8	80
46	Soluble Guanylate Cyclase Stimulators in Pulmonary Hypertension. Handbook of Experimental Pharmacology, 2013, , 279-313.	1.8	118
47	The Soluble Guanylate Cyclase Activator BAY 58-2667 Protects against Morbidity and Mortality in Endotoxic Shock by Recoupling Organ Systems. PLoS ONE, 2013, 8, e72155.	2.5	15
48	Riociguat Reduces Infarct Size and Post-Infarct Heart Failure in Mouse Hearts: Insights from MRI/PET Imaging. PLoS ONE, 2013, 8, e83910.	2.5	36
49	Cinaciguat, a novel activator of soluble guanylate cyclase, protects against ischemia/reperfusion injury: role of hydrogen sulfide. American Journal of Physiology - Heart and Circulatory Physiology, 2012, 302, H1347-H1354.	3.2	62
50	Tetrahydrobiopterin Protects Soluble Guanylate Cyclase against Oxidative Inactivation. Molecular Pharmacology, 2012, 82, 420-427.	2.3	19
51	The Rho kinase inhibitor azaindole-1 has long-acting vasodilator activity in the pulmonary vascular bed of the intact chest rat. Canadian Journal of Physiology and Pharmacology, 2012, 90, 825-835.	1.4	23
52	Nucleotidyl Cyclase Activity of Soluble Guanylyl Cyclase Î±₁Î²₁. Biochemistry, 2012, 51, 194-204.	2.5	79
53	Effects of Stimulation of Soluble Guanylate Cyclase on Diabetic Nephropathy in Diabetic eNOS Knockout Mice on Top of Angiotensin II Receptor Blockade. PLoS ONE, 2012, 7, e42623.	2.5	31
54	The Soluble Guanylate Cyclase Stimulator Riociguat Ameliorates Pulmonary Hypertension Induced by Hypoxia and SU5416 in Rats. PLoS ONE, 2012, 7, e43433.	2.5	100

#	Article	IF	Citations
55	The Soluble Guanylyl Cyclase Activator Bay 58-2667 Selectively Limits Cardiomyocyte Hypertrophy. PLoS ONE, 2012, 7, e44481.	2.5	50
56	Soluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary Disease. Circulation, 2011, 123, 2263-2273.	1.6	483
57	Riociguat for the treatment of pulmonary hypertension. Expert Opinion on Investigational Drugs, 2011, 20, 567-576.	4.1	81
58	Measuring oxidative burden and predicting pharmacological response in coronary artery disease patients with a novel direct activator of haem-free/oxidised sGC. Atherosclerosis, 2011, 218, 431-434.	0.8	22
59	Endothelin-1 overexpression restores diastolic function in eNOS knockout mice. Journal of Hypertension, 2011, 29, 961-970.	0.5	26
60	Additional stimulation of sGC on top of standard treatment with ARB`s may offer a new therapeutic approach for the treatment of diabetic nephropathy resistant to ARB treatment alone. BMC Pharmacology, 2011, 11, .	0.4	1
61	Pre-conditioning with the soluble guanylate cyclase activator Cinaciguat reduces ischaemiaâ€“reperfusion injury after cardiopulmonary bypass. European Journal of Cardio-thoracic Surgery, 2011, 39, 248-255.	1.4	26
62	Cinaciguat, a soluble guanylate cyclase activator, augments cGMP after oxidative stress and causes pulmonary vasodilation in neonatal pulmonary hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2011, 301, L755-L764.	2.9	82
63	Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase activator, BAY 60â€“2770, are not dependent on endogenous nitric oxide or reduced heme. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 300, H792-H802.	3.2	58
64	Soluble Guanylate Cyclase Stimulation Prevents Fibrotic Tissue Remodeling and Improves Survival in Salt-Sensitive Dahl Rats. PLoS ONE, 2011, 6, e21853.	2.5	88
65	Fluorescence Dequenching Makes Haem-Free Soluble Guanylate Cyclase Detectable in Living Cells. PLoS ONE, 2011, 6, e23596.	2.5	29
66	Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models. Journal of Hypertension, 2010, 28, 1666-1675.	0.5	82
67	BAY 41-2272 inhibits the development of chronic hypoxic pulmonary hypertension in rats. European Journal of Pharmacology, 2010, 647, 147-154.	3.5	21
68	Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nature Medicine, 2010, 16, 279-285.	30.7	418
69	Soluble Guanylate Cyclase. , 2010, , 301-326.		9
70	Structure of Cinaciguat (BAY 58â€“2667) Bound to Nostoc H-NOX Domain Reveals Insights into Heme-mimetic Activation of the Soluble Guanylyl Cyclase. Journal of Biological Chemistry, 2010, 285, 22651-22657.	3.4	90
71	BAY 58â€2667, a Novel NOâ€Independent Activator of Soluble Guanylate Cyclase, Protects against Ischemia/Reperfusion Injury: Potential Role of Hydrogen Sulfide Signaling. FASEB Journal, 2010, 24, 787.4.	0.5	0
72	Soluble Guanylate Cyclase Agonists Inhibit Expression and Procoagulant Activity of Tissue Factor. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 1578-1586.	2.4	11

#	Article	IF	Citations
73	Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart. Hypertension Research, 2009, 32, 597-603.	2.7	73
74	Novel soluble guanylyl cyclase stimulator BAY 41-2272 attenuates ischemia-reperfusion-induced lung injury. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2009, 296, L462-L469.	2.9	20
75	Nitric Oxideâ€"Independent Vasodilator Rescues Heme-Oxidized Soluble Guanylate Cyclase From Proteasomal Degradation. Circulation Research, 2009, 105, 33-41.	4.5	98
76	NO- and Haem-Independent Soluble Guanylate Cyclase Activators. Handbook of Experimental Pharmacology, 2009, , 309-339.	1.8	131
77	Discovery of Riociguat (BAY 63â€2521): A Potent, Oral Stimulator of Soluble Guanylate Cyclase for the Treatment of Pulmonary Hypertension. ChemMedChem, 2009, 4, 853-865.	3.2	162
78	Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation. BMC Pharmacology, 2009, 9, .	0.4	1
79	Cardioprotective effects in aged spontaneously hypertensive rats due to chronic stimulation/activation of sGC without hypotension. BMC Pharmacology, 2009, 9, P29.	0.4	13
80	Acute hemodynamic response to single oral doses of BAY 60-4552, a soluble guanylate cyclase stimulator, in patients with biventricular heart failure. BMC Pharmacology, 2009, 9, .	0.4	15
81	NO-insensitive sGCbeta1 H105F knockin mice: if NO has no place to go. BMC Pharmacology, 2009, 9, .	0.4	4
82	NO-Independent, Haem-Dependent Soluble Guanylate Cyclase Stimulators. Handbook of Experimental Pharmacology, 2009, , 277-308.	1.8	171
83	BAY 58-2667, a nitric oxide-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts. European Heart Journal, 2009, 30, 1607-1613.	2.2	42
84	Design and Synthesis of Potent and Selective Azaindoleâ€Based Rho Kinase (ROCK) Inhibitors. ChemMedChem, 2008, 3, 1893-1904.	3.2	34
85	Additional lack of iNOS attenuates diastolic dysfunction in aged ET-1 transgenic miceThis article is one of a selection of papers published in the special issue (part 1 of 2) on Forefronts in Endothelin.. Canadian Journal of Physiology and Pharmacology, 2008, 86, 353-357.	1.4	6
86	Gender-Dependent Impact of Risk Factors for Cardiovascular and Non-Cardiovascular Mortality in End-Stage Renal Disease Patients on Haemodialysis. Kidney and Blood Pressure Research, 2008, 31, 360-366.	2.0	6
87	Nitric Oxide-independent Activation of Soluble Guanylate Cyclase by BAY 60-2770 in Experimental Liver Fibrosis. Arzneimittelforschung, 2008, 58, 71-80.	0.4	71
88	Soluble CD154 Is a Unique Predictor of Nonfatal and Fatal Atherothrombotic Events in Patients Who Have End-Stage Renal Disease and Are on Hemodialysis. Journal of the American Society of Nephrology: JASN, 2007, 18, 1323-1330.	6.1	15
89	Targeting Heme-Oxidized Soluble Guanylate Cyclase in Experimental Heart Failure. Hypertension, 2007, 49, 1128-1133.	2.7	91
90	Inhaled Agonists of Soluble Guanylate Cyclase Induce Selective Pulmonary Vasodilation. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 1138-1145.	5.6	74

#	Article	IF	Citations
91	Dimerization Region of Soluble Guanylate Cyclase Characterized by Bimolecular Fluorescence Complementation in Vivo. Molecular Pharmacology, 2007, 72, 1181-1190.	2.3	45
92	Design and synthesis of the first NO- and haem-independent sGC activator BAY 58â€“2667 for the treatment of acute decompensated heart failure. BMC Pharmacology, 2007, 7, .	0.4	3
93	Targeting heme-oxidized soluble guanylate cyclase with BAY 58-2667 in experimental heart failure. BMC Pharmacology, 2007, 7, .	0.4	5
94	Oxidised sGC: a novel therapeutic target in the vasculature. BMC Pharmacology, 2007, 7, .	0.4	2
95	Selective Indole-Based ECE Inhibitors: Synthesis and Pharmacological Evaluation. ChemMedChem, 2006, 1, 96-105.	3.2	8
96	Identification of residues crucially involved in soluble guanylate cyclase activation. FEBS Letters, 2006, 580, 4205-4213.	2.8	29
97	NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nature Reviews Drug Discovery, 2006, 5, 755-768.	46.4	623
98	NOâ€independent activation of soluble guanylate cyclase prevents disease progression in rats with 5/6 nephrectomy. British Journal of Pharmacology, 2006, 148, 853-859.	5.4	66
99	Activation of Soluble Guanylate Cyclase Reverses Experimental Pulmonary Hypertension and Vascular Remodeling. Circulation, 2006, 113, 286-295.	1.6	208
100	Diabetic Endothelin B Receptorâ€“Deficient Rats Develop Severe Hypertension and Progressive Renal Failure. Journal of the American Society of Nephrology: JASN, 2006, 17, 1082-1089.	6.1	34
101	Soluble Guanylate Cyclase Stimulation on Cardiovascular Remodeling in Angiotensin IIâ€“Induced Hypertensive Rats. Hypertension, 2006, 48, 972-978.	2.7	65
102	Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. Journal of Clinical Investigation, 2006, 116, 2552-2561.	8.2	390
103	Novel, selective indole-based ECE inhibitors: Lead optimization via solid-phase and classical synthesis. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 4201-4205.	2.2	22
104	A cell-based cGMP assay useful for ultra-high-throughput screening and identification of modulators of the nitric oxide/cGMP pathway. Analytical Biochemistry, 2005, 339, 104-112.	2.4	61
105	Residues stabilizing the heme moiety of the nitric oxide sensor soluble guanylate cyclase. European Journal of Pharmacology, 2005, 513, 67-74.	3.5	33
106	Novel, Selective Indole-Based ECE Inhibitors: Lead Optimization via Solid-Phase and Classical Synthesis.. ChemInform, 2005, 36, no.	0.0	0
107	Antifibrotic effects of an sGC activator in rat models of liver fibrosis. BMC Pharmacology, 2005, 5, P24.	0.4	2
108	Formation of quasi-covalent sGC Î±1/Î²1-heterodimers by ODQ-induced oxidation of the prosthetic heme moiety. BMC Pharmacology, 2005, 5, P40.	0.4	0

#	Article	IF	Citations
109	Co-activation of soluble and particulate guanylate cyclase by BAY 58-2667 and BNP enhances cardiorenal function in experimental heart failure. BMC Pharmacology, 2005, 5, 1.	0.4	1
110	Inhaled NO and the guanylate cyclase stimulator Bay 41-2272 in oleic acid induced acute lung injury in rabbits. BMC Pharmacology, 2005, 5, P61.	0.4	4
111	Beyond NO and heme: biochemical and pharmacological opportunities. BMC Pharmacology, 2005, 5, S18.	0.4	2
112	Stimulation of soluble guanylyl cyclase inhibits mesangial cell proliferation and matrix accumulation in experimental glomerulonephritis. American Journal of Physiology - Renal Physiology, 2005, 288, F685-F693.	2.7	29
113	Effects of the sGC Stimulator BAY 41-2272 Are Not Mediated by Phosphodiesterase 5 Inhibition. Circulation, 2004, 110, e320-1; author reply e320-1.	1.6	26
114	Identification of Residues Crucially Involved in the Binding of the Heme Moiety of Soluble Guanylate Cyclase. Journal of Biological Chemistry, 2004, 279, 3025-3032.	3.4	145
115	Relaxin Is an Independent Risk Factor Predicting Death in Male Patients With End-Stage Kidney Disease. Circulation, 2004, 109, 2266-2268.	1.6	26
116	New Antithrombotics with an Indazole Structure. Archiv Der Pharmazie, 2004, 337, 311-316.	4.1	9
117	Potent cardiorenal actions in experimental heart failure with dual activation of soluble and particulate guanylate cyclases by bay 58-2667 and B-type natriuretic peptide: a novel therapeutic strategy. Journal of Cardiac Failure, 2004, 10, S90.	1.7	1
118	4-Phenyl-4H-pyrans as IKCa Channel Blockers.. ChemInform, 2003, 34, no.	0.0	0
119	Receptor binding assay for nitric oxide- and heme-independent activators of soluble guanylate cyclase. Analytical Biochemistry, 2003, 314, 162-165.	2.4	7
120	4-Phenyl-4H-pyrans as IKCa channel blockers. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 2637-2639.	2.2	62
121	Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase. European Journal of Pharmacology, 2003, 468, 167-174.	3.5	85
122	Preparation of heme-free soluble guanylate cyclase. Protein Expression and Purification, 2003, 31, 42-46.	1.3	16
123	Cardiorenal and Humoral Properties of a Novel Direct Soluble Guanylate Cyclase Stimulator BAY 41-2272 in Experimental Congestive Heart Failure. Circulation, 2003, 107, 686-689.	1.6	98
124	BAY 41-2272 Activates Two Isoforms of Nitric Oxide- Sensitive Guanylyl Cyclase. Biochemical and Biophysical Research Communications, 2002, 292, 1057-1062.	2.1	42
125	Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies. British Journal of Pharmacology, 2002, 135, 344-355.	5.4	105
126	Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies. British Journal of Pharmacology, 2002, 135, 333-343.	5.4	121

#	Article	IF	Citations
127	NOâ€•and haemâ€‘independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. British Journal of Pharmacology, 2002, 136, 773-783.	5.4	268
128	Metabolites of Orally Active NO-Independent Pyrazolopyridine Stimulators of Soluble Guanylate Cyclase. Bioorganic and Medicinal Chemistry, 2002, 10, 1711-1717.	3.0	61
129	NO-independent regulatory site of direct sGC stimulators like YC-1 and BAY 41-2272. BMC Pharmacology, 2001, 1, 13.	0.4	53
130	NO-Independent stimulators of soluble guanylate cyclase. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 781-784.	2.2	144
131	NO-independent regulatory site on soluble guanylate cyclase. Nature, 2001, 410, 212-215.	27.8	512
132	Effects of In Vivo Nitroglycerin Treatment on Activity and Expression of the Guanylyl Cyclase and cGMP-Dependent Protein Kinase and Their Downstream Target Vasodilator-Stimulated Phosphoprotein in Aorta. Circulation, 2001, 103, 2188-2194.	1.6	132
133	The Vasodilator-Stimulated Phosphoprotein (VASP): Target of YC-1 and Nitric Oxide Effects in Human and Rat Platelets. Journal of Cardiovascular Pharmacology, 2000, 35, 390-397.	1.9	34
134	Purified soluble guanylyl cyclase expressed in a baculovirus/Sf9 system: stimulation by YC-1, nitric oxide, and carbon monoxide. Journal of Molecular Medicine, 1999, 77, 14-23.	3.9	117
135	Generation and Characterization of a Stable Soluble Guanylate Cyclase-Overexpressing CHO Cell Line. Nitric Oxide - Biology and Chemistry, 1999, 3, 55-66.	2.7	23
136	Effect of YCâ€‘1, an NOâ€‘independent, superoxideâ€‘sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators. British Journal of Pharmacology, 1997, 120, 681-689.	5.4	206
137	Positive inotropic effect of exogenous and endogenous NO in hypertrophic rat hearts. British Journal of Pharmacology, 1997, 122, 813-820.	5.4	19
138	Neutral Endopeptidase Inhibition Potentiates the Effects of Natriuretic Peptides in Renin Transgenic Rats.. Hypertension Research, 1996, 19, 229-238.	2.7	17
139	Prolonged Inhibition of Neutral Endopeptidase 24.11 by Sinorphan in Stroke-Prone Spontaneously Hypertensive Rats.. Hypertension Research, 1995, 18, 137-143.	2.7	19
140	Sinorphan Improves Cardiac Structure and Function in Aged Stroke-Prone Spontaneously Hypertensive Rats. , 1995, , 70-79.		0
141	Effects of Nisoldipine on Atrial Natriuretic Peptides, Blood Pressure and Cardiac Hypertrophy in Dahl Rats. Clinical and Experimental Hypertension, 1990, 12, 1419-1436.	0.3	4
142	Role of endogenous ANP on endocrine function investigated with a monoclonal antibody. Peptides, 1990, 11, 577-582.	2.4	10
143	Different effects of ANP and nitroprusside on cyclic GMP extrusion of isolated aorta. European Journal of Pharmacology, 1989, 174, 279-282.	3.5	24
144	Modulation of atrial natriuretic peptide-induced cGMP accumulation by [Arg8]vasopressin in the cultured renal epithelial cell line, LLC-PK1. European Journal of Pharmacology, 1988, 146, 341-344.	3.5	4

#	Article	IF	Citations
145	The elevation of cyclic GMP as a response to acute hypervolemia is blocked by a monoclonal antibody directed against atrial natriuretic peptides. European Journal of Pharmacology, 1986, 129, 165-168.	3.5	30